• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , June 3

RANBAXY Laboratories Ltd has received approval from Medicines and Healthcare Products Regulatory Agency (MHRA), UK for its tablets manufacturing unit in Goa.

The company can now seek approvals through national filings and Mutual Recognition Procedures in 27 EU/EEA member states and other countries such as Australia, New Zealand and Romania.

The Goa facility also houses a cream and ointment-manufacturing block, which is approved by ANVISA, Brazil. The tablet-manufacturing unit has a capacity to produce 720 million tablets per annum.

Ranbaxy has 19 manufacturing facilities spread across seven countries which includes 10 plants in India, four dosage forms plants in the US and one dosage forms plant each in Ireland, China, Malaysia, Vietnam and Nigeria. These facilities are approved by international regulatory agencies such as USFDA, MHRA-UK, Bfarm-Germany, MCC-South Africa, ANVISA-Brazil and TGA-Australia, for a range of products. All these facilities conform and comply with GMP standards.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Fire in Sitaram Mill

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line